OPEN END TURBO CALL WARRANT - MODERNA | Delayed Deutsche Boerse AG 03:29:20 2024-06-26 EDT | ||
| 6.7 EUR | +2.29% |
|
| Current month | -6.43% | ||
| 1 month | -30.47% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 6.7 | +2.29% |
| 24-06-25 | 6.55 | +1.39% |
| 24-06-24 | 6.46 | +2.38% |
| 24-06-21 | 6.31 | 0.00% |
| 24-06-20 | 6.31 | +3.61% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 03:29 am
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | UBS |
| WKN | UL7W3R |
| ISIN | DE000UL7W3R4 |
| Date issued | 2023-09-25 |
| Strike | 67.03 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.65 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 9.42 € |
|---|---|
| Lowest since issue | 0.52 € |
| Spread | 0.04 € |
| Spread % | 0.59% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.6
USD
Average target price
145.9
USD
Spread / Average Target
+6.00%
- Stock Market
- Certificates
- Certificat
